Highlight
This analysis reveals that baseline white blood cell (WBC) count significantly modifies the impact of anti-pseudomonal antibiotic choice on 28-day mortality in sepsis. Notably, patients with a WBC count ≥16 showed improved survival with piperacillin-tazobactam compared to cefepime. These findings emerged consistently across two large clinical datasets, underscoring the potential of WBC as a biomarker for antibiotic selection and predictive enrichment in future trials.
